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Abstract 
 
The WNK-SPAK/OSR1 kinase complex is composed of the kinases WNK (with no lysine) and  
SPAK (SPS1-related proline/alanine-rich kinase) or the SPAK homolog OSR1 (oxidative-stress 
responsive kinase 1).All 3 kinases exist in same complex; SPAK/OSR1 are related to one 
another, and have redundant functions; WNKs are a separate kinase family, and operate 
upstream of both SPAK and OSR1hence WNK-SPAK/OSR1 (same issue for title – should be 
listed as “WNK-SPAK/OSR1 to capture this nuance in nomenclature) The WNK family senses 
changes in intracellular Cl- concentration, extracellular osmolarity, and cell volume and 
transduces this information to sodium (Na+), potassium (K+), and chloride (Cl-) cotransporters 
[collectively referred to a CCCs (cation-chloride transporters)] and ion channels to maintain 
cellular and organismal homeostasis and affect cellular morphology and behavior. Several genes 
encoding proteins in this pathway are mutated in human disease and the cotransporters are 
targets of commonly utilized drugs. WNKs stimulate the kinases SPAK and OSR1, which  
directly phosphorylate and stimulate Cl--importing, Na+-driven CCCs or inhibit the Cl--extruding 
K+-driven CCCs. These coordinated and reciprocal actions on the CCCs, triggered by an 
interaction between RFXV/I motifs within the WNKs and CCCs and a conserved C-terminal 
(CCT) docking domain in SPAK and OSR1, pinpoint a potentially druggable node that could be 
more effective than targeting the cotransporters directlyThe INTERACTION between the WNK 
and SPAK/OSR1 via the CCT-RFxV/I is the druggable node – the best drug available for 
inhibition of this pathway in fact disrupts the INTERACTION. In the kidney, WNK-
SPAK/OSR1 inhibition decreases epithelial NaCl reabsorption and K+ secretion to lower blood 
pressure while maintaining serum K+. In neurons, WNK-SPAK/OSR1 inhibition could facilitate 
Cl- extrusion I put “could” because action of WNK-SPAK pathway in kidney much more known 
than in neurons, though compelling data exists for this in neuronal culture systems and 
hetereologous expression systems studying neuron-specific transporters; also, I know of several 
papers including my own either in press or in submission that will make this emphasis timely. 
IMPORTANTLY, As negatively charged Cl- ions exit through activated KCC2, and are 
inhibited from entry via NKCC1, the level of intracellular Cl- is lowered; therefore, upon GABA 
binding to its GABAR (which is a Cl- permeable ion channel), Cl- rushes in, and membrane 
potential is hyperpolarized and promotes GABAergic inhibition; the opposite occurs in immature 
or diseased neurons, where elevated levels of Cl- cause Cl- to run out of cells upon GABA 
binding to GABAaRs, which causes negative charge to leave cell, membrane depolarization, and 
excitatiom…. and promote GABAergic inhibition. Such drugs could have efficacy as K+-sparing 
blood pressure-lowering agents in essential hypertension, nonaddictive analgesics in neuropathic 
pain, and mediators of ionotropic inhibition in diseases associated with neuronal hyperactivity, 
such as epilepsy, spasticity, and schizophrenia. 
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Physiology and Regulation of Cation-Chloride Cotransporters 
 
Protein kinases have become an important class of drug targets, particularly in the field 
of oncology (1). In the past decade, more than 20 different drugs targeting kinases have 
been approved for clinical use for the treatment of various types of cancer (2). However, 
the use of kinase inhibitors in other human diseases, including those with 
cardiovascular, renal, neurological, and psychiatric phenotypes, have lagged behind 
despite promising kinase targets identified by genetic studies in humans and model 
organisms (2).  
  
The electroneutral cation-Cl- cotransporters (CCCs) of the SLC12A gene family are 
secondary-active plasmalemmal ion transporters that utilize electrochemically-favorable 
cellular gradients of Na+ or K+, established by primary active transport mediated by the 
oubain-sensitive Na+/K+-ATPase, to transport Cl- (and K+) into or out of cells. Two 
branches of CCCs exist: the Cl--importing, Na+-driven CCCs (NCC, NKCC1, and 
NKCC2; collectively referred to as N[K]CCs), and the Cl--exporting, K+-driven CCCs 
(KCC1-4; collectively referred to as KCCs) (3). These evolutionarily-conserved 
transporters are among the most important mediators of ion transport in multicellular 
organisms (4), and their knockout in worms, flies, and mice demonstrate their necessity 
throughout the animal kingdom for proper function and survival (5) (Fig. 1). 
 
CCCs are critically important for human physiology. CCCs are targets of commonly 
utilized drugs, for example, furosemide (also known as Lasix) and bumetanide (also 
known as Bumex) inhibit NKCC2 and NKCC1, and thiazides inhibit NCC (Fig. 1). Three 
different CCCs are mutated in autosomal recessive disorders. Gitelmann syndrome can 
be causedOKby a loss-of function mutation in NCC (6) and Bartter syndrome can be by 
a loss-of-function mutation in NKCC2 (7); both are characterized by hypotension and 
hypokalemic alkalosis due to imbalances in renal electrolyte handling. Andermann 
syndrome can be caused by a mutation in KCC3 and is characterized by seizures, 
motor and sensory neuropathies, and agenesis of the corpus callosum due to a lack of 
KCC3 function in developing neurons (8). Alterations in CCC protein abundance or 
functional regulation, including phosphorylation, have also been demonstrated in 
numerous animal models of diseases with renal or neurological phenotypes (9).  
 
In many different cell types, the balance of Cl- import through the N[K]CCs and Cl- 
export through the KCCs sets the intracellular concentration of Cl- ([Cl-]i). This has 
important implications for several core physiological processes, including transepithelial 
solute and water transport, cell volume regulation, and neuronal excitability (4). 
Accordingly, altered CCC function contributes to NaCl-sensitive hypertension (due to 
altered epithelial transport in the distal nephron), cytotoxic edema following cerebral 
ischemia (in part due to altered regulation of cell volume), and seizures and neuropathic 
pain (due to a reduction orreduction OK loss of GABAergic inhibition, a phenomenon 
called “ionotropic disinhibition”)YES (9). In these disease states, the altered function of 
the CCCs impairs Cl- homeostasis to alter cellular structure and function. 
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Early physiological studies using radiotracer flux assays and relatively nonspecific 
kinase and phosphatase inhibitors illustrated a powerful mechanism that coordinately 
but reciprocally regulates the N[K]CCs and the KCCs in cells by a system of serine-
threonine protein kinases and phosphatases (10-19). Cell shrinkage, intracellular Cl- 
depletion, and experimental inhibition of protein phosphatase activity, promotes NCC, 
NKCC1, and NKCC2 activity, but inhibits the KCCs, by increasing transporter serine-
threonine phosphorylation. Cell swelling and intracellular Cl- accumulationhave the 
opposite effects (Fig. 2). OK This inverse regulation of Na+- and K+-driven CCCs by the 
same signals and likely the same kinase-phosphatase pathway ensures that cellular Cl- 
influx and efflux are tightly coordinated, and needless ATP expenditure is avoided. The 
importance of this phosphoregulatory mechanism is exemplified by its evolutionary 
conservation from worms to humans (20).  
 
The identity of the molecular signaling complex that controls these events remained 
unknown until the combined work of molecular genetics (21-23), physiology (24-32), 
and biochemistry (33, 34) revealed that WNKs exert their physiological effects by 
phosphorylating and activating two downstream serine/threonine protein kinases that 
are highly related to each other by sequence homology, SPAK OK[SPS1-related 
proline/alanine-rich kinase; also known as STK39 (serine threonine kinase 39)] and 
OSR1 (oxidative stress-responsive kinase 1) (33, 34). SPAK and OSR1 are functionally-
redundant kinases in experimental systems, often exist in the same kinase complex, 
and operate as central components in a switch mechanism that, through 
phosphorylation at critical N- or C-terminal residues within the transporters, stimulates 
the N[K]CCs and inhibits the KCCs (35). Inhibiting these phosphorylation events or 
promoting dephosphorylation “flips the switch” of this regulatory module to inhibit the 
N[K]CCs but activate KCCs (36). The elucidation of this switch mechanism, coupled 
with the development of the specific inhibitor STOCK1S-50699 (37) that prevents 
activation of SPAK/OSR1 thereby activating KCCs and inhibiting N[K]CCs, has set the 
stage for a next phase of exploration in which modulation of the CCCs by inhibition of 
the WNK-SPAK/OSR1 pathway for therapeutic benefit.  
 
Here, we review the molecular genetic discovery, biochemical mechanisms, and 
physiological functions of the WNK-SPAK/OSR1-CCC pathway; provide the rationale of 
why and how targeting the WNK-SPAK/OSR1 complex might be beneficial in several 
human diseases characterized by a shared pathologic signature of abnormal Cl- 
homeostasis; and explain why this approach may be particularly efficacious relative to 
existing drugs or strategies that target specific CCCs. Research on the WNK-
SPAK/OSR1 kinases exemplifies how genetics and biochemistry can synergistically be 
used to identify and target critical regulatory components within complex homeostatic 
networks and to exploit idiosyncrasies of kinase structure and unique mechanisms of 
catalytic activation to develop specific protein kinase inhibitors with therapeutic 
potential. 
 
 
Discovery and characterization of the WNK-SPAK/OSR1-CCC pathway  
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Identifying a connection between WNK and CCCs 
In 2001, Lifton and colleagues utilized positional cloning to find that mutations in WNK1 
or WNK4,OK two previously uncharacterized genes (21), caused 
pseudohypoaldosteronism type II [(PHAII)Correct – is hypo; Online Mendelian 
Inheritance in Man (OMIM) no. 145260; also known as Gordon’s Syndrome], a rare 
autosomal recessive form of thiazide-sensitive and NaCl-sensitive hypertension that is 
also characterized by high concentrations of serum K+ (hyperkalemia). This discovery 
opened an exciting new field in renal physiology, defining a hitherto unrecognized 
signaling pathway responsible for the coordination of two aldosterone-controlled 
processes (NaCl reabsorption and K+ secretion)XXXsecretion in the classical renal 
physiology sense: from blood to urine via transeipthelial transportXXX in the kidney’s 
distal nephron to regulate blood pressure and electrolyte homeostasis in humans (38). 
The WNKs were subsequently shown to regulate the phosphorylation and activities of 
two CCCs in the kidney, NCC in the distal convoluted tubule, KCC4 and NKCC2 in the 
thick ascending limb (27, 39), in concert with the renal outer medullar potassium 
channel (ROMK) (40) and the amiloride-sensitive epithelial Na+ channel (ENaC) in the 
distal tubule and collecting duct (41). The characterization of the mechanism of action of 
the WNKs on the CCCs in heterologous expression systems like oocytes and mouse 
models solved a long-standing paradox in human physiology by revealing how 
aldosterone, via differential regulation of WNK-SPAK/OSR1 activities in the presence or 
absence of angiotensin II, can affect both NaCl reabsorption and K+ secretion, and 
preferentially shunt the distal nephron into discrete activity states in which one of these 
functions is favored at the expense of the other to combat physiological perturbation 
and restore homeostasis (42, 43) (Fig. 1).  
 
Like the N[K]CCs, the KCCs are controlled by serine-threonine phosphorylation (Fig. 2) 
(36, 44, 45). Early experiments suggested the WNKs were likely key functional 
regulators (46-48). Two Thr residues in the C-terminal cytoplasmic domain, which are 
conserved in all KCC isoforms, termed Site-1 (Thr906 in KCC2; Thr991 in KCC3) and Site-
2 (Thr1007 in KCC2; Thr1048 in KCC3), play a critical role in controlling the activity of the 
KCCs and are regulated by phosphorylation by the WNKs alone XXXWNK1 regulates 
site 1, but not SPAK/OSR1; site 2 regulated by WNK1-SPAK/OSR1, hence “alone or in 
combination” XXXor in combination with SPAK/OSR1. Hypotonic high K+ conditions, 
which activate KCCs and inhibit the N[K]CCs, induce a rapid and robust 
dephosphorylation of Site-1 and Site-2 (36). Dual mutation of Site-1 and Site-2 to Ala in 
the KCCs, which prevents their phosphorylation, results in constitutively-active KCCs 
with >25-fold activity compared to wild-type KCCs in similar conditions (49). Knockdown 
of WNK1 in XXX HEK293 cells partially suppresses the phosphorylation of Site 1 in 
KCC3  49). Overexpression of WNK isoforms inhibits the KCCs, whereas 
overexpression of dominant-negative WNK3  stimulates KCC activity  (30, 46, 47, 50, 
51).  
 
Thus, WNK activity regulates the activity of N[K]CCs and KCCs through a 
phosphorylation-dependent mechanism.  
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Characterizing WNK activation mechanisms and downstream targets 
Biochemical experiments subsequently clarified the molecular mechanism by which the 
WNKs and their downstream kinase substrates, SPAK and OSR1 XXXboth can do it, 
functionally redundantXXX phosphorylate and stimulate N[K]CC activity (Fig. 3) OK(33, 
34). WNK isoforms stimulate the kinase activity of SPAK/OSR1 by phosphorylating a 
conserved Thr residue (SPAK Thr233, OSR1 Thr185) within the SPAK/OSR1 catalytic T-
loop motif (24). Mouse protein-25 (MO25) interacts with both SPAK and OSR1 to 
enhance their catalytic activities over 100-fold using in vitro CATCHtide assays (52). A 
uniqueXXXcorrect, not in any other kinases, hence druggabilityXXX, conserved C-
terminal (CCT) docking domain within SPAK/OSR1 binds RFXV/I XXXmeans 
either/orXXX motifs in the N-terminus of NCC, NKCC1, and NKCC2 (53, 54). The CCT 
domain in SPAK/OSR1 is also required for binding to and activation by WNKs, which 
also possess RFXV/I motifs (55). Following hypertonic or hypotonic low-Cl- conditions, 
WNKs and then SPAK/OSR1 are rapidly activated and SPAK/OSR1 phosphorylate 
XXXWNKs phospjhrylate SPAK/OSR1, which are the direct phosphorylators of 
NKCC1XXX a cluster of conserved Thr residues in the N-terminal cytoplasmic domain 
of the N[K]CCs (53). This mechanism of CCC phosphorylation and activation is 
conserved for NCC, NKCC1, and NKCC2. OK 
 
MO25 and MO25 are closely related and functionally redundant scaffolding proteins, 
collectively referred to as MO25/, that stimulate the activity of SPAK and OSR1 (Fig. 
3) (XX)(36).  In the presence of a MO25 subunit, SPAK/OSR1, , promote inhibition of all 
KCC isoforms by directly phosphorylating Site-2 in HEK 293 and cells (36). Inhibiting 
SPAK/OSR1 activation suppresses KCC Site-2 phosphorylation to a greater extent than 
it suppresses Site-1 phosphorylation (36). SPAK/OSR1 are required for KCC Site-2 
phosphorylation, because phosphorylation of all KCC isoforms at Site-2 is abolished in 
embryonic stem cells lacking SPAK/OSR1 kinase activity XXXcells with engineered 
point mutations silencing catalytic function of both SPAK and OSR1XXX. Furthermore, 
these SPAK/OSR1-deficient cells have increased basal activity of Cl--dependent, 
furosemide-sensitive 86Rb+ flux, consistent with KCC activation (36).  
 
Together, these data reveal that WNK-regulated SPAK/OSR1 directly phosphorylate 
NKCC1 and KCC2, promoting their stimulation and inhibition, respectively. For the 
N[K]CCs, WNK isoforms bind, phosphorylate, and activate SPAK/OSR1, which in turn 
bind and activate the N[K]CCs by directly phosphorylating a tripartite cluster of N-
terminal conserved Thr residues in each cotransporter. For the KCCs, the mechanism is 
more complex and not yet completely defined, but the current data suggest a model by 
which the WNKs bind, phosphorylate, and activate SPAK/OSR1, which in turn binds 
and partially inhibits the KCCs by directly phosphorylating Site-2. WNKs also regulate 
Site-1 phosphorylation, likely through a yet-to-be-identified kinase (Fig. 3).  
 
How are WNKs regulated? In response to a reduction in [Cl-]i, OKexposure of cells to 
hyperosmotic conditions, or XXXthese stimuli can separately activate WNK function 
XXXa reduction in cell volume, WNK isoforms are activated following 
autophosphorylation of their T-loop residue (Ser382 in WNK1) (56-58). How WNK 
isoforms sense these conditions is poorly understood. However, a potential 
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breakthrough in our understanding of how WNKs might sense chloride has emerged 
from the analysis of the crystal structure of the kinase domain of WNK1, revealing that it 
directly bound to a chloride ion (59). Biochemical and mutational data suggested that Cl- 
binding to this site inhibits autophosphorylation of WNK1, thereby inhibiting kinase 
activity (59). These results, therefore, suggest that the catalytic domains of WNKs 
function as direct Cl- sensors and that in low [Cl-]i, OK the dissociation of Cl- from the 
kinase domain of WNKs results in their activation. Although this is an attractive model, 
further work is needed to validate this model in an in-vivo setting.  
 
Identifying upstream regulators of WNK activity 
 
Whole-exome sequencing experiments by the Lifton (60) and Jeunemaitre (61) groups 
have identified mutations in the ubiquitin E3 ligase components Cullin-3 (CUL3) or 
Kelch-like 3 (KLHL3) in families with PHAII that do not have mutations in WNK-encoding 
genes. Subsequent experiments revealed CUL3 and KLHL3 form a heterodimeric 
complex, with CUL3 mediating the ubiquitylation of substrates and KLHL3 functioning 
as the substrate-recognition moiety (Fig. 3) (62-64). WNKs contain XXX,a degron 
recognixed by KLHL3 (XX). The CUL3-KLHL3 complex interacts with and ubiquitylates 
WNK isoforms; most PHAII-causing KLHL3 mutations inhibit binding to either WNK 
isoforms or CUL3 (62). Consistent with this, CUL3-KLHL3 complexes containing 
disease-associated mutations failed to ubiquitylate WNK1 in vitro (60, 62-65).  Refs 
reordered. 
 
Genetic data supporting a role for WNK-SPAK/OSR1 in essential hypertension 
 
One quarter of adults in Western societies have increased blood pressure (that is 
hypertension), which is a major risk factor for ischemic and hemorrhagic stroke, 
congestive heart failure, and end stage renal disease (66). Hypertension is a 
tremendous burden on the budgets of healthcare systems worldwide; more than $130 
billion was spent on the treatment of this condition in 2010 (66). Although lifestyle 
changes can sometimes ameloriate hypertension, most patients require drugs to lower 
blood pressure. However, many patients on multidrug regimens with currently available 
agents (for example, thiazides, Ca2+-channel blockers, angiotensin-converting enzyme 
inhibitors, and loop diuretics) have poorly controlled disease or suffer from side effects 
of the drugs, such as orthostatic hypotension and K+ wasting. The treatment of 
hypertension is, therefore, an area of continuing clinical need, and the development of 
potent drugs with fewer side effects would be useful. 
 
In the kidney, the WNK-SPAK/OSR1-mediated activation of NCC and NKCC2, which 
together mediate ~25% of renal salt reabsorption, is critical to maintain extracellular 
volume, which  in turn influences blood pressure and electrolyte homeostasis. NCC is 
inhibited by thiazides, and NKCC2 is inhibited by furosemide (Fig. 1) – these two drugs 
are some of the most common agents used in the treatment of hypertension and 
edematous states (XX)XXXthis is so common I don’t think we need citation; it’s like 
saying Tylenol is used for headacheXXX. Furthermore, the importance of the WNK-
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SPAK/OSR1-CCC pathway for renal physiology is exemplified by both human and 
mouse genetics.  
 
Starting with the upstream regulators, loss-of-function mutations in KLHL3 and CUL3, 
XXXall these mutations in are humans!XXX genes encoding negative regulators of 
WNK1 and WNK4, cause PHAII by increasing WNK1 and WNK4 abundance (61-65, 67-
70). The KLHL3 degron binding site in WNK4 encompasses residues that are mutated 
in PHAII XXXGordon’s syndrome synonomous with PHAII. PHAII disease-causing 
WNK4[D564A] and WNK4[Q565E] mutations suppress the interaction with KLHL3 (62, 
71). Moreover, the WNK4[D564A]-knockin mice display increased abundance of WNK4 
(53). A KLHL3[R528H]-knockin mouse, which mimics the most frequent KLHL3 
mutation associated with PHAII in humans, display a marked PHAII phenotype, 
including increased blood pressure and increased abundance of WNK1 and WNK4 
(XX)(72). 
 
In mice, gain-of-function mutations in WNK1 and WNK4 result in increased 
phosphorylation and activation of NCC and NKCC2, which causes hypertension in this 
mouse model of human PHAII (73-76).   In distal nephron cells, WNK4 inhibits epithelia 
sodium channels (ENaC) (77), decreased ENaC abundance compensates for the 
increased NCC activity following inactivation of the kidney-specific isoform of WNK1 and 
prevents hypertension in mouse models  (78). 
 
Genome-wide association studies of systolic and diastolic blood pressure reveal a 
strong association with common variants of SPAK and blood pressure variation (79, 80). 
SPAK-knockout mice exhibit reduced NCC activation (81) and knockin mice expressing 
SPAK or OSR1 mutants that cannot be activated by WNK isoforms exhibit reduced 
NCC- and NKCC2-activating phosphorylation, hypotension, and are resistant to 
hypertension when crossed to transgenic knockin mice bearing a PHAII-causing mutant 
WNK4 (82, 83). 
 
Loss-of-function mutations in NCC and NKCC2 cause hypotension in humans with 
Gitelman’s syndrome and Bartter’s type 1 syndrome, respectively (6, 7). Rare 
heterozygous mutations in NCC and NKCC2 alter renal NaCl handling and contribute to 
blood pressure variation and susceptibility to hypertension in the general population 
(84). A mutation in NCC okat a residue (T60M) that abolishes the critical WNK-
regulated SPAK-OSR1 activating phosphorylation event causes Gitelman's syndrome in 
Asians (85, 86).   
 
Together, these genetic data suggest that inhibition of the WNK-SPAK/OSR1 pathway 
might yield a new opportunity to develop improved antihypertensives. WNK-
SPAK/OSR1 inhibitors are likely to have increased efficacy  over either thiazides or 
furosemide alone, because they would simultaneously inhibit both NKCC2 and NCC 
activity. Additionally, WNK-SPAK/OSR1 inhibitors would likely spare K+, which would 
reduce blood pressure without the side effect of hypokalemia that is commonly 
associated with thiazides and loop diuretics (87). How can the WNK-SPAK/OSR1 
pathway be targeted to treat hypertension? 
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Strategies of WNK-SPAK/OSR1 inhibition 
 
Direct inhibition of the kinase activity of WNKs 
One approach to WNK-SPAK/OSR1 inhibition might be to exploit the atypical position of 
the catalytic lysine residue in the WNKs, which is unique compared with all other 
kinases in the human proteome (Fig. 4A)xxxagreed, we emailed the PDB #sXXX. This 
feature could be potentially utilized to develop WNK-specific ATP-competitive inhibitors. 
However, there are four different WNKs encoded by separate genes and the proteins 
have highly similar kinase domains. Furthermore, each of the  WNK genes encodes 
alternatively-spliced isoforms with discrete spatial and temporal expression profiles. For 
example, WNK1 and a renal-specific isoform of WNK1, lacking the kinase domain, bind 
one another, and this interaction is affects NCC activity (22, 88). Some reports suggest 
that WNK4 inhibits WNK1 in some contexts (89), suggesting that WNK4 inhibition might 
stimulate renal NaCl reabsorption and increase blood pressure. In contrast, reports 
characterizing WNK4-knockout mice suggest that WNK4 is the key regulator of NCC 
phosphorylation in the kidney (74, 76). Harnessing the tissue-specific localization of 
WNK isoforms will be critical in the development of drugs that exert specific effects on 
the kidney (or other target tissues, such as the central nervous system) without 
interfering with WNK activity in the other tissues in which it is present and plays a vital 
role in cellular ionic homeostasis. Presently, it is not clear which isoform(s) of WNKs 
would need to be inhibited to treat hypertension. 
 
Inhibition of the kinase activity of SPAK/OSR1  
An alternative, and potentially more straightforward approach, would be to target SPAK 
or OSR1, which are likely to function redundantly in the regulation of NCC and NKCC2. 
The SPAK and OSR1 kinase domains are ~90% identical; therefore, drugs inhibiting 
both isoforms could be developed. A dual SPAK/OSR1 inhibitor would likely be more 
efficacious at blood pressure reduction over current agents that target either NCC or 
NKCC2 alone, because SPAK/OSR1 inhibition would coordinately reduce the activities 
of both NCC and NKCC2, as well as other substrates of these kinases (for example, 
other WNK-associated ion channels like ENaC) that are important for renal physiology.  
 
Inhibiting the interaction between WNKs and SPAK/OSR1 
Because hypertension is a chronic, mostly asymptomatic condition, it will be important 
to develop WNK or SPAK/OSR1 inhibitors that are sufficiently selective that do not 
cause intolerable side effects by inhibiting other signaling components. The strategy of 
targeting the ATP-binding site of the SPAK/OSR1 or WNK kinases raises concern 
regarding the ability to develop sufficiently selective inhibitors that do not suppress other 
kinases. The development of STOCK1S-50699 has introduced the possibility of 
developing inhibitors of SPAK/OSR1 signaling by targeting the CCT domain rather than 
the kinase domain. Crystallographic analysis demonstrates that the CCT domain adopts 
a unique fold not found in other proteins and possesses a pocket that forms a network 
of interactions with the conserved RFXV/I residues on WNKs and substratesIxxxgreat 
idea!xxx(Fig. 4B) (90). A compound that binds to this structurally distinct CCT domain 
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pocket and thus blocks the interaction with the RFXI/V motif  could display high 
selectivity and not interfere with other signaling pathways.  
 
The Uchida group has exploited this biochemical information and performed high-
throughput screening of > 17,000 chemical compounds with fluorescent correlation 
spectroscopy to discover inhibitors that disrupt the WNK(RFXV/I)-SPAK/OSR1(CCT) 
interaction (37). This screen identified STOCK1S-50699 and STOCK2S-26016. IIn vitro, 
both compounds inhibit binding of the CCT domain to RFXV motifs;  in cellular studies,  
only STOCK1S-50699  suppresses SPAK/OSR1 and NKCC1 phosphorylation induced 
by hypotonic low chloride conditions (37). Neither STOCK1S-50699 nor STOCK2S-
26016 inhibited the activity of 139 different protein kinases tested (37). Further 
experiments are required to study the pharmacokinetics and pharmacodynamics of 
STOCK1S-50699 to establish whether it could be tested in preclinical animal models. 
However, these initial studies offer encouragement that targeting the CCT domain could 
lead to the development of a novel class of antihypertensive drugs. In addition to 
inhibiting the activity of NCC and NKCC2, while concurrently sparing renal K+ wasting,  
WNK-SPAK/OSR1 inhibition may elicit antihypertensive effects by decreasing NKCC1-
mediated vasoconstriction in blood vessels (81).  Such an action would offer synergistic 
effects on both renal and extrarenal targets for blood pressure reduction. 
 
Targeting KLHL3-CUL3, upstream regulators of WNK 
The WNK-SPAK/OSR1 kinase cascade could also be inhibited indirectly by targeting 
their upstream regulators. The crystal structure of the KLHL3 kelch domain in complex 
with the degron motif of WNK4 reveals that the degron motif forms an intricate web of 
interactions with conserved residues on the surface of the kelch domain β-propeller (71) 
(Fig. 4C). xxxyes that would be great!xxxMany of the disease-causing mutations in 
either WNK4 or KLHL3 inhibit binding by disrupting critical interface contacts, and are 
thus likely to result in reduced ubiquitylation and increased abundance of WNK isoforms 
(71). Indeed, KLHL3[R528H]-knockin mice,  in which Arg528 that makes critical 
interactions with the WNK4 degron motif is mutated, display a marked PHAII phenotype 
that includes increased blood pressure and increased abundance of WNK1 and WNK4 
isoforms (XX) (72). These data, therefore, point towards CUL3 and KLHL3 mutations 
resulting in inappropriate activation of the WNK-SPAK/OSR1 kinase cascade and hence 
causing hypertension through excess activity of the WNK=SPAK.OSR1-CCC 
pathway. Therefore, it would be interesting to explore whether it would be possible to 
identify compounds that promote binding of KLHL3 to either CUL3 or WNK1 and WNK4  
to lower blood pressure by stimulating ubiquitylation and degradation of WNKs.  
 
Achieving tissue-specific effects by enhancing this upstream negative regulation could 
be difficult.  WNK2 and WNK3, WNK isoforms that function in the brain , could also be 
substrates of KLHL3-CUL3 E3 ligase, because the KLHL3-binding domain of WNK4 is 
conserved in all WNK isoforms (71). Moreover, when coupled with CUL3, KLHL2, which 
shares greater than 90% homology with KLHL3, could function as an E3 ligase for all 
WNK isoforms (XX)(71). Thus, KLHL2 or KLHL3 may regulate WNKs in tissues outside 
the kidney. Consistent with this, the crystal structure of KLHL2 bound to the WNK4 
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degron has also been elucidated, indicating that KLHL2 can interact with this WNK 
isoform in a manner similar to that of KLHL3 with WNK4 (71).  
 
Inhibition of MO25, a key SPAK/OSR1 regulator 
Mouse protein-25 (MO25) alpha and beta isoforms were originally identified as critical 
scaffolding subunits required to bind to the STRAD pseudokinase and stabilize it in a 
conformation that can activate the LKB1 tumor suppressor kinase (91). Further studies 
demonstrated that MO25 isoforms have roles in binding to several STE20 family 
kinases, such as SPAK and OSR1 kinases, and induce their kinase activity for 
approximately 100-fold, and dramatically enhancing their ability to phosphorylate the ion 
cotransporters NKCC1, NKCC2 and NCC (52), whereas for MST3, MST4 and YSK1 
involved in controlling development and morphogenesis, MO25 isoforms also stimulate 
their kinase activity 3- to 4-fold based on in vitro kinase assays (52, 92, 93). However, 
the regulatory mechanism of MO25-mediated kinase activation is not fully understood. 
Structural studies of MO25 alpha-STK25 and MO25 alpha-MST3 reveal that MO25 
binds to and activates STE20 family kinases or STRAD pseudokinase through a unified 
structural mechanism, featuring an active conformation of the αC helix and A-loop 
stabilized by MO25, represent a transition and intermediate state and a fully activated 
state, respectively (94).  Therefore, compounds interfere with MO25 isoforms binding to 
SPAK and OSR1 would reduce the activity of these kinases and could potentially 
represent a strategy for reducing blood pressure. However, it would be important that 
these compounds not affect regulation of other STE20 kinases or STRAD pseudokinase 
controlled by MO25 isoforms. 
 
Targeting WNK-SPAK/OSR1 in neurological diseases associated with GABAergic 
xxxsynonomous terminologyxxx, would use GABAergicXXXdisinhibition 
 
GABA is main inhibitory neurotransmitter in the adult central nervous system, exerting 
its fast synaptic hyperpolarizing effect through the activation of ligand-gated, Cl--
permeable, GABAA receptors (GABAARs). However, in immature neurons, GABAAR-
mediated responses are depolarizing and even excitatory, which is important for 
neuronal proliferation, migration, and synaptogenesis (95, 96). A developmental 
increase in the activity of the Cl--extruding KCC2 relative to Cl--importing NKCC1 
reduces the concentration of [Cl-]i of neurons to amounts that favor GABAAR-mediated 
hyperpolarization and inhibition in the mature central nervous system. KCC2 deficiency 
in worms (97, 98), flies (99, 100), and mice (101) results in neuronal network 
hyperexcitability. In humans, pathological KCC2 functional downregulation and NKCC1 
upregulation, which increases neuronal [Cl-]i to facilitate GABAAR-mediated 
depolarization, has been demonstrated or implicated in the pathogenesis of several 
neurological disorders, including various subtypes of epilepsy, posttraumatic spasticity, 
neuropathic pain from peripheral nerve injury, and autism (102) (Fig. 4).ok  
 
Despite the role of impaired GABAergic inhibition in these conditions, existing GABAAR 
modulators, such as benzodiazepines xxxyes, I am sure of this, major side effectsxxx or 
barbiturates, are rarely successfully used for treatment because of their narrow 
therapeutic window and unwanted side effects, such as sedation or motor impairment. 
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Furthermore, in some situations, such as neonatal seizures, these drugs have 
paradoxical depolarizing and excitatory effects due to the increased concentraitons of 
[Cl-]i in immature or injured neurons. Given these limitations of targeting GABAAR 
directly, a promising “indirect” approach to anti-epileptic, analgesic, or anti-spasmodic 
drug development might be the modulation of neuronal Cl- gradients through NKCC1 
inhibition and KCC2 activation (103). Targeting these CCCs would not affect neuronal 
excitability directly, but would reduce neuronal excitability by lowering [Cl-]i to restore 
endogenous inhibition. This approach would likely yield more specificity xxxyes, GABA 
affects both GABAA and GABAB receptors, as do GABA ergic drugs, but GABAA 
receptors are more relevant for the pathologies I am discussing herexxx and a more 
favorable side effect profile than existing GABAergic agents. although drugs exist to 
inhibit the N[K]CCs, these drugs generally have poor penetration into the central 
nervous system (104). However, prodrug forms of bumetanide that have improved BBB 
permeability show therapeutic potential (105). Large-scale screening efforts have 
identified drugs that inhibit (106) or activate (107) KCC2. Because the CCCs work in 
concert with one another to achieve homeostasis , it is unknown whether functional 
compensation may occur through other CCC family members. For example,  
populations of post-synaptic cortical neurons have NKCC1, KCC2, and KCC3. The 
optimal drug would be one that targets the influx and efflux CCCs simultaneously, yet 
with opposite effects – thereby synergistically achieving net Cl- influx or efflux (9) (Fig. 
4).xxxok 
 
 
Indeed, genetic or pharmacological inhibition of WNK-SPAK/OSR1 activity would 
promote cotransporter dephosphorylation, inhibiting NKCC1 and activating KCC2, with 
anticipated net effects of enhancing cellular Cl- extrusion. In neurons, enhancing cellular 
Cl- extrusion would facilitate GABAAR-mediated hyperpolarization and thus inhibit 
neuronal activity. We, therefore, postulate that regulation of NKCC1 and KCC2 by 
WNK-SPAK/OSR1-mediated phosphorylation may be a key determinant of the 
molecular mechanism underlying the paradoxical depolarizing (excitatory) effect of 
GABA in hyperexcitalbe disease states. Thus, inhibition of WNK-SPAK/OSR1 in these 
states might provide a means of enhancing Cl- extrusion and facilitating inhibition 
through combined inhibitory and stimulatory effects on NKCC1 and KCC2, respectively. 
These efforts may prove useful for multiple syndromes that are associated with 
depolarizing responses to GABA and altered Cl- homeostasis (108-114). Genetic 
mutation that inhibits the kinase activity of WNK3, which is abundantly expressed in the 
developing brainxxxyes, is an effective means of concurrently inhibiting NKCC1 activity 
and stimulating KCC2 activity in heterologous expression system like oocytes (46, 47).  
 
Mutations in a nervous system-specific isoform of WNK1, HSN2xxx, no, the isoform is 
termed HSN2, hence the accepted nomenclature “WNK1/HSN2”, have been found in a 
disease with symptoms that include congenital pain insensitivity, hereditary sensory and 
autonomic neuropathy type II (HSANII) (115). The gene encoding HSN2 is highly 
expressed in the dorsal horn of the spinal cord, a key site of expression of the gene 
encoding KCC2. In the spinal cord dorsal horn, normally inhibitory GABAergic 
interneurons synapse with both presynaptic (primary sensory) and postsynaptic (lamina 
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I) dorsal horn neurons to modulate afferent input. In neuropathic pain states, such as 
those induced by peripheral nerve injury, GABA disinhibition due to a pathological 
decrease in KCC2 activity and the resulting increase in [Cl-]i  causes hyperpolarizing 
GABA synaptic currents to become depolarizing, which lowers the threshold for A-fiber-
mediated transmission to central nociceptive lamina I neurons (116, 117). In this 
situation, a positive modulator of KCC2 would be expected to provide effective therapy 
by restoring neuronal anion gradients and GABAergic inhibition (107). Indeed, drugs 
that enhance KCC2 activity have been developed and exhibit efficacy in cell models and 
and in animal models of neuropathic pain. Targeting WNK-SPAK/OSR1 in this context 
might also be valuable. The gene encoding HSN2 is also highly expressed in the dorsal 
root ganglion, where the genes encoding NKCC1 and KCC3,(but not the one encoding 
KCC2 are highly expressed, and these cotransporters are responsible for the unusually 
high [Cl-]i in these primary sensory neurons and GABA-stimulated depolarization (118). 
Data supporting these hypotheses are emerging and targeting the WNK-SPAK/OSR1-
CCC pathway in these types of neuronal hyperexcitability disorders will be rich areas of 
future investigation. 
 
Conclusion and future directions 
 
The importance of coordinating cellular Cl- influx and efflux in renal epithelia and 
neurons is well known (4_ENREF_4, 119). The finding that SPAK/OSR1 phosphorylate 
and thereby trigger activation of the Na+-driven, Cl--influx CCCs (NKCC1, NKCC2, and 
NCC) and also phosphorylate and inhibit K+-driven, Cl--efflux CCCs (KCC1, KCC2, 
KCC3, and KCC4) helps explain how the CCCs are reciprocally and coordinately 
controlled to achieve homeostasis in multiple tissues. The WNK-SPAK/OSR1-CCC 
pathway is critically important for normal human physiology, making it an attractive 
target for drug development. Analysis of humans and mice with mutations in this 
pathway has illustrated the potential benefits of targeting this pathway in human 
diseasesOne specific mechanism for interfering with this pathway is by the targeting of 
the CCT domain within SPAK/OSR1, which interferes with the activation of SPAK/OSR1 
by WNK. A disease  amenable to inhibition of the WNK-SPAK/OSR1 pathway would 
include essential hypertension, one of the most common diseases of the industrialized 
world. In addition, given the recent enthusiasm for the discovery of KCC2 activators 
tthat enhance neuronal Cl- extrusion in diseases with GABAergic disinhibition, exploring 
the effects of WNK-SPAK/OSR1 inhibition in ameliorating seizures, neuropathic pain, 
spasticity, and other diseases associated with neuronal excitability is compelling. WNK-
SPAK/OSR1 inhibition not only enhances cellular Cl- extrusion by concurrently inhibiting 
NKCC1-mediated Cl- influx through NKCC1 and activating KCC-mediated Cl- efflux 
through the KCCs, but the WNK-SPAK/OSR1 cascade also serves as both the sensor 
and transducer of Cl- perturbation. Therefore, targeting these kinases might also 
prevent inhibition of feedback on other CCCs or molecules that aim to equilibrate ion 
gradients, offering a coordinated, multivalent, and sustained effect.  
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Figure 1. WNKs regulate NCC and NKCC2 through the kinases SPAK and OSR1 to 
achieve blood pressure and K+ homeostasis humans. WNK1 and WNK4 
areabundant in the kidney. Inhibition of WNKs in the kidney is predicted to elicit a  K+-
sparing, anti-hypertensive effect by reducing the reasorption of NaCl by NCC in the 
distal collecting and connecting tubules (DCT/CNT) and by NKCC2 in the thick 
ascending limb (TAL). Red asterisks depict nodes in the signaling pathway where 
inhibition would be expected to decrease blood pressure. The blue asterisk depicts a 
node where stimulation would be expected to decrease blood pressure. Mendelian 
diseases labeled in blue are those resulting from mutation of the indicated gene in 
humans. PHAII = pseudohypoaldosteronism type II. CNT = connecting tubule. TAL = 
thick ascending limb. STOCK1S-50699, a recently-developed WNK-SPAK/OSR1 
inhibitor. 
  
Figure 2. The N[K])CCs and KCCs are reciprocally regulated by reversible serine-
threonine phosphorylation. Hypotonic low Cl- conditions or a reduction in cell volume 
(not shown) lead to phosphorylation and activation of the N(K)CCs and phosphorylation 
and inhibition of the KCCs to promote Cl- and water influx through N[K]CCs. If 
intracellular Cl- become too high or cell volume increases, the cotransporters become 
dephosphorylated because their upstream kinases are inhibited and Cl- and water efflux 
through KCCs occurs to restore ion and osmotic homeostasis. Cl- and water are 
indicated by the blue fill. 
 
Figure 3. Domains and sites important for regulation of and signaling through the 
WNK-SPAK/OSR1 pathway. Proteins with slashes indicate that multiple isoforms have 
the same properties. For SPAK/OSR1, the residue numbering above the protein 
represents SPAK and the residue numbering below represents OSR1. Kinase X refers 
to a yet-unidentified kinase that is regulated by WNKs and mediates the direct 
phosphorylation and inhibition of site 1 on the KCCs. Rbx and Nedd8 are part of the 
ubiquitin ligase complex. E1 and E2 represent the two enzymes involved in transfer of 
ubiquitin (Ub) onto itself to form polyubiquitin chains. STOCK15-5069 is a small 
molecule inhibitor that blocks the interaction between SPAK/OSR1 and WNK by binding 
to the CCT domain. 
 
Figure 4. Structural insights into the WNK-SPAK/OSR1 pathway. (A) The kinase 
domain of WNK showing the unusually positioned Lys in the catalytic site. Based on 
PDB XXX. (B) The CCT domain bound to an XXX peptide from WNKX. Based on PDB 
XXX. (C) The kelch domain of KLHL3 bound to the WNKX degron motif. Based on PDB 
XXX. 
 
Figure 5. A strategy to facilitate neuronal Cl- extrusion by inhibiting the WNK-
SPAK/OSR1 pathway. Top shows that switch in the abundance of NKCC and KCC2 
that occurs during postnatal development. This switch converts the GABAergic signal 
from depolarizing to hyperpolarizing. Left middle shows that in developing neurons and 
in some diseased neurons, [Cl-]i (blue fill) is increased due to  high NKCC1 activity, low 
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KCC2 activity, or both. Activation of GABAAR results in Cl- efflux, depolarization and 
excitation..  Right middle shows that in healthy mature neurons, [Cl-]i because KCC2 
activity predominates and  GABAAR activation results in Cl- influx and hyperpolarization.  
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